Immunostimulatory activity of polysaccharide-poly(I:C) nanoparticles

Biomaterials

Volumn 32, Issue 18, 2011, Pages 4275-4282

  Tincer, Gizem ^a   Yerlikaya, Seda ^a   Yagci, Fuat C ^a   Kahraman, Tamer ^a   Atanur, Osman M ^b   Erbatur, Oktay ^b   Gursel, Ihsan ^a  

^a BILKENT UNIVERSITY   (Turkey)

^b CUKUROVA UNIVERSITY   (Turkey)

Author keywords

Immunogenicity; Nanoparticles; Poly(I:C); Polysaccharides; Targeted delivery system; TLR

Indexed keywords

DELIVERY SYSTEMS; IMMUNOGENICITY; INFECTIOUS DISEASE; OVALBUMINS; POLY(I:C); PROTEIN ANTIGENS; SIGNALING CASCADES; STAND -ALONE; TARGETED DELIVERY; TLR; UP-REGULATION;

ATOMIC FORCE MICROSCOPY; LEAD OXIDE; NITRIC OXIDE; NUCLEIC ACIDS; POLYSACCHARIDES; SIGNAL TRANSDUCTION;

NANOPARTICLES;

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; NANOPARTICLE; NITRIC OXIDE; POLYINOSINIC POLYCYTIDYLIC ACID; POLYSACCHARIDE; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ARTICLE; ATOMIC FORCE MICROSCOPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; FEMALE; IMMUNOGENICITY; IMMUNOSTIMULATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION;

ADJUVANTS, IMMUNOLOGIC; AGARICALES; ANIMALS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNIZATION; INTERFERON INDUCERS; INTERLEUKIN-16; INTERLEUKIN-18; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROSCOPY, ATOMIC FORCE; NANOPARTICLES; NITRIC OXIDE; POLY I-C; POLYSACCHARIDES; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

BASIDIOMYCOTA; MUS;

EID: 79955157178     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.01.028     Document Type: Article

References (36)

1. Janeway C.A., Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002, 20:197-216.
2. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001, 1:135-145.
3. Takeda K., Akira S. Toll-like receptors in innate immunity. Int Immunol 2005, 17:1-14.
4. Ishii K.J., Koyama S., Nakagawa A., Coban C., Akira S. Host innate immune receptors and beyond: making sense of microbial infections. Cell Host Microbe 2008, 3:352-363.
5. Schmidt K.N., Leung B., Kwong M., Zarember K.A., Satyal S., Navas T.A., et al. APC-independent activation of NK cells by the Toll-like receptor 3 agonist double-stranded RNA. J Immunol 2004, 172:138-143.
6. Barry M.E., Pinto-Gonzalez D., Orson F.M., McKenzie G.J., Petry G.R., Barry M.A. Role of endogenous endonucleases and tissue site in transfection and CpG-mediated immune activation after naked DNA injection. Hum Gene Ther 1999, 10:2461-2480.
7. Sparwasser T., Miethke T., Lipford G., Borschert K., Hacker H., Heeg K., et al. Bacterial DNA causes septic shock. Nature 1997, 386:336-337.
8. Krieg A.M., Efler S.M., Wittpoth M., Adhami Al, M.J., Davis H.L. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 2004, 27:460-471.
9. Monteith D.K., Henry S.P., Howard R.B., Flournoy S., Levin A.A., Bennett C.F., et al. Immune stimulation-a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des 1997, 12:421-432.
10. Sparwasser T., Hultner L., Koch E.S., Luz A., Lipford G.B., Wagner H. Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. J Immunol 1999, 162:2368-2374.
11. Lipford G.B., Sparwasser T., Zimmermann S., Heeg K., Wagner H. CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. J Immunol 2000, 165:1228-1235.
12. Borges O., Silva M., de Sousa A., Borchard G., Junginger H.E., Cordeiro-da-Silva A. Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen. Int Immunopharmacol 2008, 8:1773-1780.
13. Fischer S., Schlosser E., Mueller M., Csaba N., Merkle H.P., Groettrup M., et al. Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response. J Drug Target 2009, 17:652-661.
14. Schlosser E., Mueller M., Fischer S., Basta S., Busch D.H., Gander B., et al. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 2008, 26:1626-1637.
15. Gursel I., Gursel M., Ishii K.J., Klinman D.M. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol 2001, 167:3324-3328.
16. Suzuki Y., Wakita D., Chamoto K., Narita Y., Tsuji T., Takeshima T., et al. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. Cancer Res 2004, 64:8754-8760.
17. Xie H., Gursel I., Ivins B.E., Singh M., O'Hagan D.T., Ulmer J.B., et al. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect Immun 2005, 73:828-833.
18. Zaks K., Jordan M., Guth A., Sellins K., Kedl R., Izzo A., et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 2006, 176:7335-7345.
19. Mozafari M.R. Liposomes: an overview of manufacturing techniques. Cell Mol Biol Lett 2005, 10:711-719.
20. Crommelin D.J., Storm G. Liposomes: from the bench to the bed. J Liposome Res 2003, 13:33-36.
21. Chirila T.V., Rakoczy P.E., Garrett K.L., Lou X., Constable I.J. The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides. Biomaterials 2002, 23:321-342.
22. Kim Y.G., Park J.H., Shaw M.H., Franchi L., Inohara N., Nunez G. The cytosolic sensors Nod1 and Nod2 are critical for bacterial recognition and host defense after exposure to Toll-like receptor ligands. Immunity 2008, 28:246-257.
23. Lin Z.B., Zhang H.N. Anti-tumor and immunoregulatory activities of Ganoderma lucidum and its possible mechanisms. Acta Pharmacol Sin 2004, 25:1387-1395.
24. Bourquin C., Anz D., Zwiorek K., Lanz A.L., Fuchs S., Weigel S., et al. Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. J Immunol 2008, 181:2990-2998.
25. Wilson K.D., de Jong S.D., Tam Y.K. Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy. Adv Drug Deliv Rev 2009, 61:233-242.
26. Mizu M., Koumoto K., Anada T., Matsumoto T., Numata M., Shinkai S., et al. A polysaccharide carrier for immunostimulatory CpG DNAs to enhance cytokine secretion. J Am Chem Soc 2004, 126:8372-8373.
27. Shimada N., Coban C., Takeda Y., Mizu M., Minari J., Anada T., et al. A polysaccharide carrier to effectively deliver native phosphodiester CpG DNA to antigen-presenting cells. Bioconjug Chem 2007, 18:1280-1286.
28. Mizu M., Koumoto K., Kimura T., Sakurai K., Shinkai S. Protection of polynucleotides against nuclease-mediated hydrolysis by complexation with schizophyllan. Biomaterials 2004, 25:3109-3116.
29. Chan G.C., Chan W.K., Sze D.M. The effects of beta-glucan on human immune and cancer cells. J Hematol Oncol 2009, 2:25.
30. Zhu X.L., Lin Z.B. Effects of Ganoderma lucidum polysaccharides on proliferation and cytotoxicity of cytokine-induced killer cells. Acta Pharmacol Sin 2005, 26:1130-1137.
31. Hua K.F., Hsu H.Y., Chao L.K., Chen S.T., Yang W.B., Hsu J., et al. Ganoderma lucidum polysaccharides enhance CD14 endocytosis of LPS and promote TLR4 signal transduction of cytokine expression. J Cell Physiol 2007, 212:537-550.
32. Lin Y.L., Liang Y.C., Lee S.S., Chiang B.L. Polysaccharide purified from Ganoderma lucidum induced activation and maturation of human monocyte-derived dendritic cells by the NF-kappaB and p38 mitogen-activated protein kinase pathways. J Leukoc Biol 2005, 78:533-543.
33. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 1992, 6:3051-3064.
34. Chin, M. P., Schauer, D. B. and Deen, W. M., Nitric oxide, oxygen, and superoxide formation and consumption in macrophages and colonic epithelial cells. Chem Res Toxicol.
35. Gursel I., Gursel M., Yamada H., Ishii K.J., Takeshita F., Klinman D.M. Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol 2003, 171:1393-1400.
36. Giulietti A., Overbergh L., Valckx D., Decallonne B., Bouillon R., Mathieu C. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 2001, 25:386-401.